Compare LINK & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | ESLA |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 48.9M |
| IPO Year | N/A | N/A |
| Metric | LINK | ESLA |
|---|---|---|
| Price | $3.85 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.67 | ★ $16.00 |
| AVG Volume (30 Days) | 51.3K | ★ 89.7K |
| Earning Date | 11-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,023,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $34.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.99 | $0.73 |
| 52 Week High | $10.10 | $3.15 |
| Indicator | LINK | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 33.05 |
| Support Level | $3.70 | $0.93 |
| Resistance Level | $3.98 | $1.17 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 62.93 | 9.48 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.